Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT05972655
- Locations
- 🇨🇳
Sir Run Run Shao hospital, Hanzhou, Zhejiang, China
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Yu jiren
- Target Recruit Count
- 30
- Registration Number
- NCT05970627
- Locations
- 🇨🇳
Ningbo First Hospital, Ningbo, Zhejiang, China
🇨🇳Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Akeso
- Target Recruit Count
- 90
- Registration Number
- NCT05960955
- Locations
- 🇨🇳
Tianjin Provincial Tumor Hospital, Tianjin, China
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT05945823
- Locations
- 🇺🇸
University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States
🇺🇸Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 100
- Registration Number
- NCT05914389
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT05914610
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT05891171
- Locations
- 🇺🇸
Mayo Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Florida, Jacksonville, Florida, United States
🇺🇸Affinity Health Hope and Healing Cancer Services, LLC, Hinsdale, Illinois, United States
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 53
- Registration Number
- NCT05877573
- Locations
- 🇨🇳
Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Yu jiren
- Target Recruit Count
- 314
- Registration Number
- NCT05872685
- Locations
- 🇨🇳
Lishui Central Hospital, Lishui, Zhejiang, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Taizhou Hospital, Taizhou, Zhejiang, China
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05867121
- Locations
- 🇺🇸
UCLA University of California Los Angeles, Los Angeles, California, United States
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.